The multifunctional TDN-FA/PL1/Pcsk9-siRNA demonstrates efficacy and safety in CRC, thereby broadening the utilization of DNA nanotechnology for novel treatments across different cancer types. This evidence concerns the gene PCSK9 and cancer.